A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | MicrobiomeTrials← Back to trialsNCT07491172
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-06-21Est. Completion: 2027-06
Enrollment target: 90 participants Locations- Integrity Clinical Research, Hialeah, Florida, United States
- Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
- Flourish Orlando, Orlando, Florida, United States
- United Medical Research, Port Orange, Florida, United States
- University of Rochester, Rochester, New York, United States
- Duke Early Phase Clinical Research, Durham, North Carolina, United States
- Peters Medical Research, High Point, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Oregon Health & Science University (OHSU), Portland, Oregon, United States
- Royal Adelaide, Adelaide, Australia
- CORE Research, Brisbane, Australia
- Royal Prince Alfred Hospital, Camperdown, Australia
- Austin Health, Heidelberg, Australia
- Monash Medical Center, Melbourne, Australia
- Aotearoa, Auckland, New Zealand
- NZCR, Christchurch, New Zealand
- Royal Papworth Hospital, Cambridge, United Kingdom
- Barts, London, United Kingdom
Other microbiome trials you might be interested in
Heart RateCraniovertebral AnglePostureOcclusal Mouthguards
The stomatognathic system is functionally connected to the overall body system. Occlusal modification using intraoral de…
Valencia, SpainCompleted Apr 18, 2026
HypertensionHypertension,Essential
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 i…
Adelaide, AustraliaEst. completion Jul 31, 2026
Richmond Pharmacology, London, United KingdomModerate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the po…
Birmingham, United StatesEst. completion Oct 24, 2030